All these findings have extended the scenario of mechanisms of drugs such as actinomycin D, 5-FU, and oxaliplatin that specifically impact ribosome biogenesis for the treatment of cancers lacking active p53, thereby highlighting the importance of human rpL3 as a critical mediator of cell response to chemotherapy. Here, TP53 is linked to cancer.